NEDD9 and acute myeloid leukemia: To investigate whether HSCT might overcome the adverse prognostic effect caused by NEDD9 overexpression in AML, we analysed the prognostic impact of HSCT in NEDD9 overexpressed and underexpressed groups, respectively.